Analysis Of Income And Expense [Abstract]

Biotest AG - Filing #6464577

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
7,262,000,000 EUR
6,846,000,000 EUR
Material income and expense [abstract]
Research and development expense
568,000,000 EUR
668,000,000 EUR
Finance income (cost)
339,000,000 EUR
400,000,000 EUR
Sales and marketing expense
499,000,000 EUR
504,000,000 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of joint ventures accounted for using equity method
141,000,000 EUR
28,000,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
EUR
336,000,000 EUR
EUR
42,000,000 EUR
30,000,000 EUR
264,000,000 EUR
EUR
1,278,000,000 EUR
20,000,000 EUR
1,267,000,000 EUR
EUR
31,000,000 EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
336,000,000 EUR
1,278,000,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.